Adaptive Biotechnologies has unveiled new data highlighting the significant role of measurable residual disease (MRD) assessment in the treatment of blood cancer and drug development.
The findings, centred around the company’s clonoSEQ test, are detailed in over 65 abstracts being presented at the 66th Annual Meeting of the American Society of Hematology in San Diego, US, taking place from 6 to 10 December.
Go deeper with GlobalData
The Phase III data from the ECOG-ACRIN EA4151 trial suggest that for mantle cell lymphoma subjects in first complete remission with undetectable MRD, autologous haematopoietic cell transplantation may not offer additional benefits.
Subjects with undetectable MRD from peripheral blood were randomised to receive either transplantation plus maintenance rituximab (MR) or MR alone.
With a median follow-up of 2.7 years, the interim analysis revealed no significant difference in overall survival (OS) between the two groups.
Furthermore, the FELIX trial demonstrated that deep molecular remission, defined as MRD levels below 10⁻⁶, is associated with improved outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) treated with obecabtagene autoleucel.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAn 84% of treatment responders who underwent clonoSEQ MRD testing achieved MRD <10⁻⁶, correlating with more durable responses and higher event-free survival and OS rates than in subjects with higher MRD levels.
Adaptive Biotechnologies MRD chief commercial officer Susan Bobulsky said: “At this year’s ASH meeting, we’re proud to see clonoSEQ’s pivotal role in shaping the future of blood cancer care.
“The breadth of data presented highlights the growing recognition of clonoSEQ as a powerful tool for accelerating patient access to novel therapies, optimising clinical care and delivering actionable insights that improve outcomes for patients living with a variety of blood cancers.”
clonoSEQ, the first Food and Drug Administration (FDA)-cleared in vitro diagnostic test for MRD detection in bone marrow for multiple myeloma and B-cell acute lymphoblastic leukaemia, is available as a laboratory-developed test. The platform is also used to detect the condition in blood or bone marrow from chronic lymphocytic leukaemia patients.
It leverages the company’s immune medicine platform to identify and quantify specific DNA sequences found in malignant cells.
In April 2023, Adaptive entered a translational collaboration with Takeda to incorporate its clonoSEQ Assay in clinical trials across Takeda’s haematologic malignancy portfolio.
